Literature DB >> 17288642

Distribution of emm genotypes among group A streptococcus isolates from patients with severe invasive streptococcal infections in Japan, 2001-2005.

T Ikebe1, K Hirasawa, R Suzuki, H Ohya, J Isobe, D Tanaka, C Katsukawa, R Kawahara, M Tomita, K Ogata, M Endoh, R Okuno, Y Tada, N Okabe, H Watanabe.   

Abstract

We surveyed emm genotypes of group A streptococcus (GAS) isolates from patients with severe invasive streptococcal infections during 2001-2005 and compared their prevalence with that of the preceding 5 years. Genotype emm1 remained dominant throughout 2001 to 2005, but the frequency rate of this type decreased compared with the earlier period. Various other emm types have appeared in recent years indicating alterations in the prevalent strains causing severe invasive streptococcal infections. The cover of the new 26-valent GAS vaccine fell from 93.5% for genotypes of isolates from 1996-2000 to 81.8% in 2001-2005.

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17288642      PMCID： PMC2870682          DOI： 10.1017/S0950268807007984

Source DB:  PubMed          Journal:  Epidemiol Infect        ISSN： 0950-2688            Impact factor:   2.451


  7 in total

1.  Sequencing emm-specific PCR products for routine and accurate typing of group A streptococci.

Authors:  B Beall; R Facklam; T Thompson
Journal:  J Clin Microbiol       Date:  1996-04       Impact factor: 5.948

Review 2.  Streptococcal M protein: molecular design and biological behavior.

Authors:  V A Fischetti
Journal:  Clin Microbiol Rev       Date:  1989-07       Impact factor: 26.132

3.  Antiphagocytic activity of streptococcal M protein: selective binding of complement control protein factor H.

Authors:  R D Horstmann; H J Sievertsen; J Knobloch; V A Fischetti
Journal:  Proc Natl Acad Sci U S A       Date:  1988-03       Impact factor: 11.205

4.  Defining the group A streptococcal toxic shock syndrome. Rationale and consensus definition. The Working Group on Severe Streptococcal Infections.

Authors: 
Journal:  JAMA       Date:  1993-01-20       Impact factor: 56.272

5.  [Case report of toxic shock-like syndrome due to group A streptococcal infection].

Authors:  Y Shimizu; A Ohymama; K Kasama; M Miyazaki; K Ooe; Y Ookochi
Journal:  Kansenshogaku Zasshi       Date:  1993-03

6.  Safety and immunogenicity of 26-valent group a streptococcus vaccine in healthy adult volunteers.

Authors:  Shelly A McNeil; Scott A Halperin; Joanne M Langley; Bruce Smith; Andrew Warren; Geoffrey P Sharratt; Darlene M Baxendale; Mark A Reddish; Mary C Hu; Steven D Stroop; Janine Linden; Louis F Fries; Peter E Vink; James B Dale
Journal:  Clin Infect Dis       Date:  2005-09-12       Impact factor: 9.079

7.  Changing prevalent T serotypes and emm genotypes of Streptococcus pyogenes isolates from streptococcal toxic shock-like syndrome (TSLS) patients in Japan.

Authors:  T Ikebe; N Murai; M Endo; R Okuno; S Murayama; K Saitoh; S Yamai; R Suzuki; J Isobe; D Tanaka; C Katsukawa; A Tamaru; A Katayama; Y Fujinaga; K Hoashi; J Ishikawa; H Watanabe
Journal:  Epidemiol Infect       Date:  2003-06       Impact factor: 2.451
  7 in total
  11 in total

1.  Streptococcus pyogenes bacteraemia, emm types and superantigen profiles.

Authors:  S Rantala; S Vähäkuopus; T Siljander; J Vuopio; H Huhtala; R Vuento; J Syrjänen
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2011-08-30       Impact factor: 3.267

2.  Molecular epidemiology of sil locus in clinical Streptococcus pyogenes strains.

Authors:  Céline Plainvert; Márcia Dinis; Miriam Ravins; Emanuel Hanski; Gérald Touak; Nicolas Dmytruk; Agnès Fouet; Claire Poyart
Journal:  J Clin Microbiol       Date:  2014-03-26       Impact factor: 5.948

3.  Epidemiology, outcome and emm types of invasive group A streptococcal infections in Finland.

Authors:  T Siljander; O Lyytikäinen; S Vähäkuopus; M Snellman; J Jalava; J Vuopio
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2010-06-20       Impact factor: 3.267

4.  Highly frequent mutations in negative regulators of multiple virulence genes in group A streptococcal toxic shock syndrome isolates.

Authors:  Tadayoshi Ikebe; Manabu Ato; Takayuki Matsumura; Hideki Hasegawa; Tetsutaro Sata; Kazuo Kobayashi; Haruo Watanabe
Journal:  PLoS Pathog       Date:  2010-04-01       Impact factor: 6.823

5.  Burden of group A streptococcal meningitis in Salvador, Brazil: report of 11 years of population-based surveillance.

Authors:  Milena Soares Santos; Guilherme de Sousa Ribeiro; Tainara Queiroz Oliveira; Renan Cardoso Nery Santos; Edilane Gouveia; Kátia Salgado; Daniele Takahashi; Cleuber Fontes; Leila Carvalho Campos; Mitermayer Galvão Reis; Albert Icksang Ko; Joice Neves Reis
Journal:  Int J Infect Dis       Date:  2008-11-18       Impact factor: 3.623

6.  Beta-hemolytic streptococcal infections in trauma patients.

Authors:  P Mathur; N Bhardwaj; G Gupta; P Punia; V Tak; M C Misra
Journal:  Eur J Trauma Emerg Surg       Date:  2013-08-27       Impact factor: 3.693

Review 7.  Disease manifestations and pathogenic mechanisms of Group A Streptococcus.

Authors:  Mark J Walker; Timothy C Barnett; Jason D McArthur; Jason N Cole; Christine M Gillen; Anna Henningham; K S Sriprakash; Martina L Sanderson-Smith; Victor Nizet
Journal:  Clin Microbiol Rev       Date:  2014-04       Impact factor: 26.132

8.  Epidemiology and distribution of 10 superantigens among invasive Streptococcus pyogenes disease in Germany from 2009 to 2014.

Authors:  Matthias Imöhl; Christina Fitzner; Stephanie Perniciaro; Mark van der Linden
Journal:  PLoS One       Date:  2017-07-18       Impact factor: 3.240

9.  Emergence of Streptococcus pyogenes emm102 causing toxic shock syndrome in Southern Taiwan during 2005-2012.

Authors:  Jiun-Nong Lin; Lin-Li Chang; Chung-Hsu Lai; Hsi-Hsun Lin; Yen-Hsu Chen
Journal:  PLoS One       Date:  2013-12-09       Impact factor: 3.240

Review 10.  Molecular and genomic characterization of pathogenic traits of group A Streptococcus pyogenes.

Authors:  Shigeyuki Hamada; Shigetada Kawabata; Ichiro Nakagawa
Journal:  Proc Jpn Acad Ser B Phys Biol Sci       Date:  2015       Impact factor: 3.493
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.